Checkpoint Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q4 2014 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Checkpoint Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q4 2014 to Q2 2024.
  • Checkpoint Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$6.67M, a 58.8% increase year-over-year.
  • Checkpoint Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$35.5M, a 42.4% increase year-over-year.
  • Checkpoint Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$52.1M, a 10.6% increase from 2022.
  • Checkpoint Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$58.3M, a 2.84% decline from 2021.
  • Checkpoint Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$56.7M, a 144% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$35.5M -$6.67M +$9.52M +58.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$45M -$10.9M +$7.14M +39.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 -$52.1M -$10.2M +$6.48M +38.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-22
Q3 2023 -$58.6M -$7.7M +$2.96M +27.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$61.6M -$16.2M -$2.03M -14.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$59.6M -$18.1M -$1.22M -7.25% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 -$58.3M -$16.6M +$13.1M +44.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 -$71.5M -$10.7M +$614K +5.44% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$72.1M -$14.2M -$5.01M -54.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$67.1M -$16.9M -$10.3M -159% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$56.7M -$29.8M -$19.5M -191% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$37.2M -$11.3M -$6.33M -128% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$30.9M -$9.16M -$4.48M -95.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$26.4M -$6.52M -$3.18M -95.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$23.2M -$10.2M -$1.39M -15.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 -$21.8M -$4.94M +$290K +5.54% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$22.1M -$4.67M +$153K +3.17% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 -$22.3M -$3.34M +$2.59M +43.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 -$24.9M -$8.86M +$3.04M +25.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$27.9M -$5.23M +$4.15M +44.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$32M -$4.83M +$1.85M +27.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$33.9M -$5.93M +$2.85M +32.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$36.7M -$11.9M -$5.95M -100% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 -$30.8M -$9.39M -$3.44M -57.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$27.4M -$6.68M -$206K -3.18% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$27.1M -$8.78M -$4.37M -99% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 -$22.8M -$5.94M +$2.4M +28.7% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 -$25.2M -$5.95M -$811K -15.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-02
Q2 2017 -$24.4M -$6.47M -$1.05M -19.5% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$23.3M -$4.41M -$1.14M -34.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 -$22.2M -$8.34M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-16
Q3 2016 -$5.14M -$1.46M -39.7% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-03
Q2 2016 -$5.42M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 -$3.27M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 -$3.68M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q4 2014 $0 Nov 10, 2014 Dec 31, 2014 10-K/A 2017-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.